在患有急性心力衰竭的患者中,由功能修改的N终端前激素B型尿素的预后值
Rui Zhu1, Yaoyao Wang1, Lili Liu1
1Department of Nephrology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
European journal of internal medicine
|June 22, 2025
概括
N-终端前激素B型性尿素 (NT-proBNP) 预测心力衰竭 (HF) 的不良结果. 它的预后值受到功能的改变,并且随着时间的推移而减少,强调动态监测.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 生物标志物研究 生物标志物研究
背景情况:
- 关于NT-proBNP在心力衰竭 (HF) 的预后价值,关于功能和随访持续时间进行了辩论.
- 了解这些因素对于HF患者的准确风险分层至关重要.
研究的目的:
- 调查功能和随访时间对急性HFNT-proBNP预后意义的影响.
- 评估估计的膜过率 (eGFR) 如何改变NT-proBNP与不良结果之间的关联.
主要方法:
- 全国范围的前性队列研究,包括4766名因急性HF住院的成年患者.
- 用于分析与NT-proBNP水平相关的风险的Cox和Poisson回归模型.
- 通过功能 (eGFR) 修改效果被特别测试.
主要成果:
- 较高的NT-proBNP水平与所有原因和心血管死亡率的增加有关.
- 在平均4.6年的随访期间,NT-proBNP与死亡风险之间的关联减少了.
- 功能改变NT-proBNP的预后值:相对风险减弱,但绝对风险增加较低的eGFR.
结论:
- 在HF中,NT-proBNP显示了带有不良结果的分级关联.
- 预后意义受功能的影响,功能受损的绝对风险更高.
- 对NT-proBNP的动态监测至关重要,特别是在功能受损的患者中.
相关概念视频
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
223
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
223
01:29Heart Failure II: Pathophysiology
59
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
59
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
524
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
524
01:30Heart Failure V: Medical Management
34
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
34
01:24Serum Studies: Renal Function Tests
53
Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
53
01:17Pathophysiology of Heart Failure
1.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K